BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 34053447)

  • 1. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysis.
    Lu Y; Yang G; Xiao Y; Zhang T; Su F; Chang R; Ling X; Bai Y
    Breast Cancer; 2020 Sep; 27(5):903-911. PubMed ID: 32338339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing.
    Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT
    Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
    Zhong G; Lou W; Shen Q; Yu K; Zheng Y
    Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    PLoS One; 2021; 16(11):e0254283. PubMed ID: 34797837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer.
    Wu J; Cai Y; Zhao G; Li M
    J Clin Lab Anal; 2021 Jun; 35(6):e23779. PubMed ID: 33934391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
    Fan CN; Ma L; Liu N
    J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
    Zhai Q; Li H; Sun L; Yuan Y; Wang X
    Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening and identification of potential biomarkers in triple-negative breast cancer by integrated analysis.
    Guo J; Gong G; Zhang B
    Oncol Rep; 2017 Oct; 38(4):2219-2228. PubMed ID: 28849078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
    Chou CW; Huang YM; Chang YJ; Huang CY; Hung CS
    Int J Med Sci; 2021; 18(12):2521-2531. PubMed ID: 34104083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer.
    Naorem LD; Muthaiyan M; Venkatesan A
    J Cell Biochem; 2019 Apr; 120(4):6154-6167. PubMed ID: 30302816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of dysregulated microRNAs associated with diagnosis and prognosis in triple‑negative breast cancer: An in silico study.
    Fan C; Liu N
    Oncol Rep; 2019 Jun; 41(6):3313-3324. PubMed ID: 30942465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNA-135b Contributes to
    Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
    Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments.
    Zhang M; Zhang F; Wang J; Liang Q; Zhou W; Liu J
    J Transl Med; 2024 May; 22(1):423. PubMed ID: 38704606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCC9, NKAPL, and TMEM132C are potential diagnostic and prognostic markers in triple-negative breast cancer.
    Zhang X; Kang X; Jin L; Bai J; Zhang H; Liu W; Wang Z
    Cell Biol Int; 2020 Oct; 44(10):2002-2010. PubMed ID: 32544280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Hub Genes to Regulate Breast Cancer Spinal Metastases by Bioinformatics Analyses.
    He Y; Cao Y; Wang X; Jisiguleng W; Tao M; Liu J; Wang F; Chao L; Wang W; Li P; Fu H; Xing W; Zhu Z; Huan Y; Yuan H
    Comput Math Methods Med; 2021; 2021():5548918. PubMed ID: 34055036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.
    Min L; Zhang C; Qu L; Huang J; Jiang L; Liu J; Pinello L; Yuan GC; Shou C
    Oncotarget; 2017 Mar; 8(13):21938-21953. PubMed ID: 28423538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer.
    Hu Y; Zou D
    PLoS One; 2021; 16(12):e0260811. PubMed ID: 34965257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selected ideal natural ligand against TNBC by inhibiting CDC20, using bioinformatics and molecular biology.
    Liu N; Wang X; Zhu Z; Li D; Lv X; Chen Y; Xie H; Guo Z; Song D
    Aging (Albany NY); 2021 Oct; 13(20):23702-23725. PubMed ID: 34686627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.